A preliminary trial of doxorubicin in advanced breast cancer and other malignant disease.
Doxorubicin in a dose of 60 mg/m(2) has been used in the treatment of 23 patients with advanced malignant disease, 18 of whom had carcinoma of the breast. The drug has significant clinical activity on its own, prolonged dosage may be required to obtain a response, and there is a risk of cerebral metastases becoming manifest during treatment which is otherwise successful. Cardiac toxicity appears to be acceptably low with this dose regimen.
D000505:Alopecia / Q000139:chemically induced; D000564:Ameloblastoma / Q000188:drug therapy; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D013964:Thyroid Neoplasms / Q000188:drug therapy
D006454:Hemoglobins; D004317:Doxorubicin